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the effects of thyrotropin releasing hormone (TRH) and its 
stable analogue, CG3703, on cardiac output (thermodilution, 
Cardiomax) and regional blood flow (BF; directional pulsed 
Doppler technique) were investigated in hypovolemic hypoten-
sion in the rat. In urethan-anesthetized rats TRH (0.5 or 2 mg/ 
kg ia) or CG3703 (0.05 or 0.5 mg/kg ia) reversed the bleeding 
(27% of the blood volume)-induced decreases in mean arterial 
pressure (MAP) and cardiac index (Cl) and increased the heart 
rate (HR) and total peripheral resistance index (TPRI) in a 
dose-related manner. In the conscious rat exposed to a 45% 
hemorrhage, CG3703 (0.5 mg/kg ia) significantly raised MAP, 
HR, and TPRI with maximum changes of +67 ± 6 (SE) mmHg, 
+ 123 ± 30 beats/min, and + 101 ± 2%, respectively. CG3703 
(0.5 mg/kg ia) also further enhanced the hemorrhage-induced 
reduction of hindquarter, mesenteric, and renal BF. The 
changes in BF in saline-treated vs. CG3703-treated rats 2 h 
after the bleeding were -32 ± 6 vs. -55 ± 6% (P < 0.001) in 
hindquarter, -9 ± 8 vs. -61 ± 11% (P < 0.001) in mesenteric, 
and -2 ± 9 vs. -33 ± 9% (P < 0.01) in the renal artery; the 
changes in vascular resistance +30 ± 7 vs. +309 ± 167% (P < 
0.001) in hindquarter, -4 ± 8 vs. +349 ± 244% in the mesen-
teric, and -10 ± 9 vs. +80 ± 10% (P <: 0.01) in the renal artery. 
The survival rate after the 45% hemorrhage was significantly 
reduced by both TRH and CG3703. The results suggest that 
TRH reverses the hypovolemic hypotension mainly by increas-
ing vascular resistance and causing impairment of BF to vital 
organs, thereby exacerbating the shock and leading to an in-
creased mortality. 
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THYROTROPIN RELEASING HORMONE (TRH) is a tripep-
tide found in cell borlies and nerve fibers of mammalian 
brain and spinal cord (for review see Ref. 20). In addition 
to its endocrine effects, TRH induces strong cardiores-
piratory stimulation that is of central origin (2, 5, 8, 16). 
Recent sturlies have shown that TRH is able to antago-
nize the hypotension in various experimental shock 
models (for review see Ref. 3). Systemic injection of 
TRH following endotoxic or hemorrhagic shock in the 
rat significantly improved the cardiovascular function 
(13, 15). TRH also reversed hypotension induced by 
leukotriene (LT)D4, platelet activating factor, soybean 
lipoxygenase, or antigen-induced anaphyla:x;is in the con-
scious guinea pig (7, 17, 18). 
The beneficial effect of TRH in experimental shock 
appears to be due to an action on the central nervous 
system, since doses of TRH that have no effect after 
sytemic injection reverse shock (14) and improve survival 
( 1) after intracerebroventricular administration. Fur-
thermore, the pressor effect of TRH on LTD4-induced 
hypotension is totally abolished in the pithed rat in which 
the complete central nervous system is destroyed (9). In 
intact rats, TRH induces marked rises of plasma Ievels 
of norepinephrine and epinephrine (4, 8), and, at least 
in endotoxic shock in the rat, the reversal of hypotension 
by TRH seems to require a functioning adrenal medulla 
(14). Recently, the beneficial effect of TRH on survival 
following anaphylactic shock in mice was also found to 
be mediated by the sympatho-adrenomedullary system 
(1). In some models of experimental shock, a physiolog-
ical antagonism of the endogenous opioids by TRH has 
also been suggested (for review see Ref. 6). However, 
little is known of the discrete hemodynamic mechanisms 
underlying the effects of TRH in circulatory shock. W e 
now report the effects of systemically injected TRH on 
cardiac output and total peripheral resistance following 
hemorrhagic shock in both anesthetized and conscious 
rats. Because TRH is rapidly inactivated after systemic 
administration (20), the effect of a degradation stable 
TRH analogue, CG3703 (10), on thesevariables was also 
examined. Furthermore, the effect of CG3703 on regional 
blood flow distribution and on blood gases and Iactate 
after bleeding was investigated in the conscious rat. 
Earlier sturlies have shown that CG3703 is morepotent 
than TRH in eliciting neuropharmacological effects such 
as activity in antidepressant screening tests, reversal of 
the effects of diverse central nervous system depressants, 
and promoting arousal when given alone, but it appears 
tobe equipotent to TRH in endocrine tests (10, 19). 
MATERIALSAND METHODS 
Male Sprague-Dawley rats (260-360 g) were used in 
all experiments. After surgical operations, the chroni-
cally instrumented animals were housed individually in 
plastic cages (21 X 27 x 16 cm, W x LX H) with food 
and water ad libitum. 
Measurement of Cardiac Output 
The cardiac output was measured by the thermodilu-
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tion technique (Cardiomax), which, due to its methodo-
logical simplicity, is useful in conscious rats. It has been 
shown previously that the cardiac output values obtained 
by this method correlate well with the cardiac output 
values obtained by electromagnetic flowmetry in the rat 
(24). The rats were anesthetized with urethan (1.2 g/kg 
ip), and PE-50 tubing was inserted into the femoral 
arteries. An incision was then made at the midline of the 
neck from the cricoid to the clavicle, and PE-50 tubing 
was inserted into the right atrium through the external 
jugular vein. The left common carotid artery was exposed 
and ligated. A reusable Teflon thermistor (MX2-780-33 
model THMP f 1.5, Columbus Instruments, Columbus, 
OH) was advanced thro'ugh the carotid artery and into 
the ascending aorta (placement above the aortic valve 
was confirmed in each animal at the end of the experi-
ment and by the shape of the dilution curve before the 
probe was finally sutured to the neck muscles). One 
arterial line was connected to a pressure transducer 
(Narco RP 1500i), and recordings ofblood pressure (sys-
tolic, diastolic, mean) and heart rate were carried out by 
the Narcotrace 80 computerized dynograph. The cardiac 
output was measured by thermodilution technique with 
the thermistor attached to the computerized Cardiomax 
II (CMx2-780-k with the microprobe option R, Columbus 
Instruments). The dead space of the venous line was first 
flushed with 0.05 ml of 0.9% (wt/vol) NaCl (saline) at 
room temperature, 22°C; afterabrief stabilization period 
(10 s to ensure normal core temperature) an additional 
injection of 0.2 ml normal saline (22°C) was rapidly 
injected using a 1-ml syringe. Cardiac output was re-
corded by the following method: a control period of 30 
min included two to three cardiac output measurements 
to test for consistency and placement of the probe, and 
also to get control values for mean arterial pressure and 
heart rate. The timer on the automatic data collection 
system was started, and data points were taken at to, ts, 
t10, t1s, tao, t,5, and tso min. Hypovolemic hypotension was 
induced by bleeding through the other arterialline 27% 
ofthe blood volume (5 ml·300 g-1 ·5 min-1). The bleeding 
was started at t0 , and the drug injection was made be-
tween t5 and t10, at approximately ts. The drugs were 
injected slowly (over 30 s) into the arterial line. Total 
peripheral resistance was calculated by dividing the mean 
arterial pressure by the cardiac output; values of cardiac 
output and TPR were further indexed per unit of weight 
(kg). 
In additional rats the effect of CG3703 on cardiac 
output and total peripheral resistance was investigated 
in the conscious state. The rats were anesthetized with 
pentobarbitone (40 mg/kg ip), and the surgical proce-
dures were performed as described above. All vascular 
lines were tunneled beneath the skin and exteriorized 
from the back of the neck. The lines were secured by a 
soft spring wire attached by an adhesive tape collar at 
the back of the neck and outside of the cage. The exper-
iments were conducted 24 h after the surgery. Hypovo-
lemic hypotension was induced by bleeding through the 
arterial line 45% of the blood volume (8.5 ml· 300 g-1 • 5 
min-1), and the recordings of blood pressure, heart rate, 
and cardiac output were followed in saline- and TRH-
treated animals as described above. The 45% hemorrhage 
was used in these experiments, because earlier studies in 
our laboratory have shown that this volume of bleeding 
results in about 90% survival in conscious rats. Further-
more, due to the thermodilution method, the animals 
were volume loaded with at least 3 ml of saline during 
the experiment. 
Regional Blood Flow Measurements With Directional 
Pulsed Doppler Technique 
Another set of rats (n = 13) was used to study the 
effect of CG3703 on regional blood flow and vascular 
resistance by the directional pulsed Doppler method. By 
using this technique we are not able to quantitate the 
actual blood flow. However, Haywood and co-workers 
(12) have shown that the velocity signals recorded from 
the Doppler flow probes are directly and reliably propor-
tional to changes in true volume flow measured by elec-
tromagnetic flowmeter. The animals were anesthetized 
with ketamine-acepromazine, 0.13 ml/100 g of a solution 
of ketamine (100 mg/ml) and acepromazine (1 mg/ml), 
and miniaturized Doppler flow probes (Valpey-Fisher) 
were implanted around the abdominal aorta, superior 
mesenteric artery, and the left renal artery according to 
the method described earlier (12). Briefly, a midline 
laparotomy was made, and 4-mm lengths of the lower 
abdominal aorta below the left renal, the superior mes-
enteric, and the left renal arteries were carefully isolated 
with the aid of a dissecting microscope. Miniaturized 
Doppler flow probes were then sutured around each 
vessel. The wire Ieads were tunneled beneath the skin 
and exteriorized at the nape of the neck where they were 
soldered to a connector plug that was fixed to the ani-
mal's skull with small screws and dental acrylic. Polyeth-
ylene catheters (PE-50) were implanted in the femoral 
arteries for measurements of blood pressure and heart 
rate and for drug injections. The catheters were led 
beneath the back skin to exit at the nape of the neck and 
were then secured by a spring wire as described above. 
The animals were allowed to recover from · the surgery 
for 2-3 days. On the day of the experiment the rat was 
connected to the flow probe wire connectors, and the 
connector line was suspended from the top of the ani-
mal's home cage to allow freedom of movement during 
the experiment. Regional blood flow was measured with 
a directional pulsed Doppler flowmeter (model 545c-3, 
University of Iowa Bioengineering Facility). The arterial 
line was attached to a pressure transducer (as above), 
and the blood pressure, heart rate, and regional blood 
flows were continuously recorded on the N arco dyno-
graph. V ascular resistance was calculated by dividing the 
mean arterial pressure by blood velocity (Doppler shift 
in kHz). Changes in blood flow and vascular resistance 
are expr.essed as a percent of control values. Since in 
these experiments the animals were not volume loaded, 
the 27% hemorrhage was chosen. Hypovolemic hypoten-
sion was induced by bleeding through the other arterial 
line 27% of the blood volume (5 ml·300 g-1 ·5 min-1), 
and saline or CG3703 (0.5 mg/kg) was injected into the 
arterialline 2-3 min after bleeding. 
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Assay of Blood CO:~, 0:~, pH, and Lactates 
In aseparate set of rats (n = 18) the effects of TRH 
or CG3703 on blood gases and Iactate were studied in 
conscious rats exposed to 45% hemorrhage. Arteriallines 
were implanted into femoral vessels under halothane 
anesthesia (2% halothane in 02) 24 h before the experi-
ments. Hypovolemic hypotensionwas induced by bleed-
ing through the arterialline 8.5 ml· 300 g-1 • 5 min - 1, and 
an equal volume of saline, TRH (2 mg/kg), or CG3703 
(0.5 mg/kg) was injected into the arterialline 2-3 min 
after the bleeding. The first and the last 0.5 ml of this 
blood was saved for the assays, and additional 0.5-ml 
blood samples were withdrawn from the arterialline 30, 
60, 90, and 120 min after the bleeding. lmmediately after 
the withdrawal of these blood samples, an equal volume 
of fresh blood from other rats was used to replenish the 
amount withdrawn. Blood C02, 02, and pH were assayed 
on whole blood (0.25 ml) using a Corning pH-blood gas 
165/2 analyzer. Blood Iactate was assayed with a com-
mercial kit (Sigma, St. Louis, MO). 
Drugs Used 
The following drugs were used: thyrotropin releasing 
hormone (TRH) (Sigma) and the degradation-stabilized 
TRH analogue, CG3703 (6-methyl-5-oxo-thiomorpholi-
nyl-3-carbonyl-histidyl-prolinamide), kindly provided by 
Dr. Flohe from Grünenthai GmbH, Aachen, FRG, were 
both dissolved in saline. 
A MEAN ARTERIAL PRESSURE 
Statistical Analysis of the Data 
Data in text and figures are represented as means ± 
SEM for the number of rats indicated. Analysis of vari· 
ance (ANOV A) with repeated measures and ANOVA 
followed by Student-Newman-Keuls test were both used 
for statistical analysis of the data. Significance of sur-
vival rate was determined by means of Fisher's exact 
probability test. 
RESULTS 
Effects of TRH and CG3703 in Anesthetized Rats 
Effects on blood pressure and heart rate (Fig. 1). Bleed-
ing through a femoralline (5 ml·300 g-1 ·5 min-1) in-
duced sharp decreases in mean arterial and pulse pres-
sures. Injection of TRH at doses of 0.5 mg/kg or 2 mg/ 
kg into the arterialline a few minutes after the bleeding 
reversed the bleeding-induced hypotension in a dose-
related manner. The heart rate significantly increased 
only after the highest dose of TRH. CG3703 (0.5 mg/kg 
ia) induced short-lasting increments of blood pressure 
and a delayed tachycardia, whereas the higher dose 
caused strong sustained rises of blood pressure and heart 
rate. 
Effects on cardiac index and total peripheral resistance 
index (Fig. 2). Bleeding (5 ml·300 g-1 ·5 min-1) signifi-
cantly decreased cardiac index and total peripheral re-
sistance. TRH (0.5 mg/kg or 2 mg/kg ia) dose-depend-
ently reversed the decreases in cardiac index and total 
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FIG. 1. Effect of thyrotropin releasing hormone (TRH) and TRH analogue CG3703 on cardiovaacular variables 
following hemorrhage (27%) in the urethan-anesthetized rat. TRH (0.5 or 2 mgfkg), CG3703 (0.05 or 5 mg/kg), or 
88line was injected (/, arrow) into the arterialline 2-3 min after bleeding (5 ml-300 g-1 -5 min-1). Values represent 
means ± SEM; •, P < 0.05 and •a, P < 0.01 vs. saline-treated group; t, P < 0.05 and ta, P < 0.01low vs. high dose 
(Student-Newman-Keuls test). 
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FIG. 2. Effect of thyrotropin releasing hormone (TRH) and TRH analogue CG3703 on cardiac inde:x: and total 
peripheral resistance index following hemorrhage (27%) in the urethan-anesthetized rat. TRH (0.5 or 2 mg/kg), 
CG3703 (0.05 or 0.5 mg/kg), or salinewas injected (I, arrow) into the arterialline 2-3 min after bleeding (5 ml·300 
g-1 • 5 min-1). Values represent means ± SEM; •, P < 0.05 and •a, P < 0.01 vs. saline-treated group; t, P < 0.05 and 
ta, P < O.Ollow vs. high dose (Student-Newman-Keuls test). 
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FIG. 3. Dose-response relationship of thyrotropin releasing hor-
mone (TRH) and CG3703 to induce cardiovascular changes in the 
anesthetized rat exposed to 27% hemorrhage. Solid lines, TRH; dotted 
lines, CG3703. Data from Figs. 1 and 2. Area scores represent areas 
under the time-response curve of the drug in each case. MAP, mean 
arterial pressure; HR, heart rate; TPRI, total peripheral resistance 
index; CI, cardiac index. 
peripheral resistance index caused by the bleeding. The 
increase in total peripheral resistance induced by TRH 
was short-lasting: the maximum rise became apparent a 
few minutes after · the drug injection, arid the effect 
subsided in about 10-25 min. Cardiac index, on the other 
hand, increased immediately after the drug administra-
tion and remained high during the whole observation 
period (60 min). 
CG3703 (0.05 mg/kg or 0.5 mg/kg) injected into the 
arterial line a few minutes after the bleeding caused a 
sustained increment in cardiac index and tncreased total 
peripheral resistance in a dose-related manner. The rel-
ative activity (represented as area s.core for each variable) 
of TRH and CG3703 to induce cardiovascular changes 
in hemorrhaged rats is demonstrated in Fig. 3. Compared 
with TRH, CG3703 was 10 times more potent in eliciting 
increases in cardiac index, 15 times more potent in 
causing rises of mean arterial pressure, 250 times more 
potent in increasing total peripheral resistance index, 
and 400 times more potent in producing tachycardia. 
Effects ~~ CG3703 in Conscious Rats 
Effects on blood pressure and heart rate (Fig. 4). On the 
basis of the experiments performed on the anesthetized 
rats, the 0.5 mg/kg dose of the TRH analogue, CG3703, 
was chosen to be used in all studies on conscious animals. 
Bleeding ofthe ratsvia the arterialline (8.5 ml·300 g-1 • 
5 min - 1) induced sharp decreases in mean arterial and 
pulse pressures with variable effect on the heart rate. 
The mean blood pressure after the hemorrhage was 4 7 ± 
3 mmHg in the control group and 54 ± 5 mmHg in the 
drug-treated group. The TRH analogue induced a signif-
icant reversal of the bleeding-induced hypotension and a 
long-lasting increase in the heart rate. When given to 
normotensive rats, CG3703 increased the mean arterial 
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FIG. 4. Effect of thyrotropin releasing hormone (TRH) analogue CG3703 on cardiovascular variables in intact 
conscious rats and rats exposed to 45% hemorrhage. CG3703 (0.5 mg/kg) or salinewas injected (1, arrow) into the 
arterialline at t8• Values represent means ± SEM. 
pressure, pulse pressure, and heart rate with maximum 
rises of + 16 ± 4 mmHg, + 15 ± 3 mmHg, and +84 ± 15 
beats/min (P < 0.01), respectively. 
Effects on cardiac index and total peripheral resistance 
(Fig. 5). Bleeding the rats at a rate of 8.5 ml· 300 g-1 • 5 
min-1 caused decreases in cardiac output and peripheral 
resistance. The drops in cardiac index and total periph-
eral resistance were -250 ± 15 ml· min - 1 • kg-1 and -0.04 
± 0.01 mmHg-ml-1 ·min-1 -kg-1 in the control group and 
-230 ± 25 ml-min-1 -kg-1 and -0.05 ± 0.01 mmHg-1 • 
ml-1 -min-1 -kg-1 in the drug-treated group. CG3703 (0.5 
mg/kg ia) injected 2-3 min after the end of the bleeding 
produced a long-lasting rise oftotal peripheral resistance 
with no significant improvement in the cardiac index. 
On the contrary, the recovery of cardiac function was 
significantly impaired by CG3703 so that the increments 
of cardiac index 90 min after the end of the bleeding 
were +54± 25 ml-min-1-kg-1 (+22 ± 10%) in the drug-
treated rats and +129 ± 25 ml-min-1 -kg-1 (+60 ± 15%) 
in the control group. The corresponding changes 2 h 
after the end of the bleeding were significantly different 
in CG3703-treated versus control groups (/ = 2.43, P = 
0.02). In intact (nonbled) animals the same dose of 
CG3703. significantly increased the cardiac index but had 
no significant effect on total peripheral resistance. 
Effects on regional blood flow and vascular resistance 
(Fig. 6). Bleeding at a rate of 5 ml· 300 g-1 • 5 min-1 
decreased the blood flow in hindquarter, mesenteric, and 
renal vasculature. In spite of a significant improvement 
in blood pressure and heart rate, CG3703 (0.5 mg/kg ia) 
significantly enhanced the bleeding-induced impairment 
of blood flow in all these vascular beds.-' The blood flows 
in control versus CG3703-treated rats 2 h after the 
bleeding were -32 ± 6% versus -55 ± 6% (P < 0.001) 
in the hindquarters, -9 ± 8% versus -61 ± 11% (P < 
0.001) in the mesenteric artery, and -2.9% versus -33 ± 
9% (P < 0.01) in the renal artery. The corresponding 
changes in the vascular resistance 2 h after the bleeding 
were +30 ± 7% versus +309 ± 167% in the hindquarters 
(P < 0.001), -4 ± 8% versus +349 ± 244% in the 
mesenteric, and -10 ± 9% versus +80 ± 10% (P < 0.01) 
in the renal artery. 
Effect on blood C02, 02, pH, and Iactate (Table 1). 
Bleeding at a rate of 8.5 ml-300 g-1 -5 min-1 induced 
significant increases in blood Iactate and Po2, and sig-
nificantly decreased blood Pco2, but had no effect on 
blood pH. Systemic injection of TRH (2 mg/kg) or 
CG3703 (0.5 mg/kg) into the arterialline 2-3 min after 
the end 'of the bleeding significantly attenuated the hy-
peroxemia produced by hemorrhage but bad no effect on 
blood pH, C02, or lactic acid Ievel. 
Effect on survival (Table 2). TRH (2 mg/kg ia) signifi-
cantly decreased survival 1 h after the hemorrhage in the 
conscious rat, while the TRH analogue, CG3703 (0.5 mg/ 
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FIG. 5. Effect oftbyrotropin releasing bormone (TRH) analogue CG3703 on cardiac index (Cl) and total peripberal 
resistance index in intact conscious rats and rats exposed to 45% hemorrhage. Saline was injected (I, arrow) into the 
arterial line at ta. Values represent means ± SEM. CG3703-induced increase in CI was significant at P < 0.05, 
compared with control group during 1st 45 min (ANOV A with repeated measures). 
kg ia), induced a significant reduction on the 24-h sur-
vival rate after the 8.5 ml·300 g-1·5 min-1 bleeding. 
DISCUSSION 
TRH and its pyroglutamyl analogue CG3703 (10) re-
versed the hleeding-induced hypotension and increased 
the heart rate in a dose-related manner in both urethan-
anesthetized and conscious rats. Systemic injection of 
CG3703 (0.5 mg/kg) raised blood pressure and heart rate 
also in the intact conscious rat. Due to its prolonged 
action, CG3703 was more potent than TRH in inducing 
cardiovascular changes. Earlier studies have shown that 
the long-lasting biological activity of CG compounds is 
due to their resistance to the TRH degradating pyroglu-
tamate aminopeptidases (10). 
TRH is known to be a potent pressor and tachycardic 
agent in anesthetized (5, 16) and conscious rats (8). 
These actions of TRH were believed to underlie the 
improved cardiovascular function in various experimen-
tal shock models including the hypovolemic shock (for 
review see Ref. 3). The cardiovascular effects of TRH 
are likely to be due to an action of the agent on the 
central nervous system, since the doses needed to elicit 
cardiovascular changes after systemic injections are a 
thousandfold higher than the doses used intracerebro-
ventricularly or for injections into discrete brain nuclei 
(5, 8, 14, 16). A peripheral component in the beneficial 
cardiovascular effects of TRH in endoto:xic shock has 
also been suggested, since the pressor and tachycardic 
effects of centrally administered TRH in this particular 
shock model were partly blocked by adrenal medullec-
tomy, whereas the effects of systemically injected TRH 
remained unaffected (14). However, a peripheral mech-
anism of action of TRH is contradicted by the recent 
finding that the reversal of LTD.-induced hypotension 
by TRH is totally abolished in the pithed rat, in which 
the entire central nervous system and cardiac reflexes 
are eliminated (9). 
Concomitantly with the reversal of hypovolemic hy-
potension, TRH and the analogue, CG3703, dose-de-
pendently antagonized the bleeding-induced decline in 
cardiac index and markedly increased total peripheral 
resistance in the urethan -anesthetized rat. The cardio-
vascular changes caused by TRH were relatively short-
lasting, whereas CG3703, at the highest dose, produced 
prolonged increases in blood pressure, heart rate, and 
total peripheral resistance but only a brief elevation of 
cardiac index. The increase in cardiac index by CG3703 
in anesthetized rats might be due to antagonism by TRH 
analogues of the effects of anesthesia (19, 20), since in 
the conscious rat exposed to the hemorrhage the TRH 
analogue, CG3703, caused a marked, prolonged increase 
in vascular resistance with no beneficial effect on the 
cardiac index. This is further supported by the fact that 
the base-line Ievels for cardiac index were significantly 
reducEd by anesthesia as reported also by others earlier 
(22). Furthermore, in conscious rats, CG3703 signifi-
cantly delayed the recovery of cardiac function after the 
bleeding. 
In conscious intact rats CG3703 induced the pressor 
and tachycardic responses that were accompanied by an 
increase in cardiac index while total peripheral resistance 
remained unchanged. Studies in progress in our labora-
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FIG. 6. Effect of thyrotropin releasing hormone (TRH) analogue CG3703 on regional blood flow and vascular 
resistance in hindquarter, mesenteric, and renal vascular beds following hemorrhage (27%) in the conscious rat. 
CG3703 (0.5 mg/kg) or saline was injected (1, arrow) into the arterial line 2-3 min after bleeding (5 ml· 300 g-1 • 
min-1). Values represent means ±SEM. 
tory (unpublished observations) confirmed this special 
pattern of hemodynamic changes also after systemic 
injection of TRH (2 mg/kg ia) in the normovolemic 
conscious rat. Thus the hemodynamic mechanisms un-
derlying the pressor effect of TRH in hypovolemic hy-
potension seem to differ from those mediating its hyper-
tenaive responsein the normovolemic state. The marked 
reduction of blood volume caused by the bleeding (45%) 
and/or by the excessive increase in afterload to the heart 
due to the strongly elevated vascular resistance by TRH 
may account for these differences. 
The present findings on the effect of CG3703 on the 
blood flow further support this view: in conscious rats 
exposed to a 27% hemorrhage, the TRH analogue, 
CG3703, significantly enhanced the bleeding-induced im-
pairment of local blood flow in hindquarter, mesenteric, 
and renal vasculature, and strongly increased the vas-
cular resistance in hindquarter and renal and, to a lesser 
degree, in mesenteric vasculature. In the intact rat we 
recently reported increased blood flow in hindquarter 
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TABLE 1. Elfect of TRH and CG3703 on blood gases, pH, and lactic acid following 45% hemorrhage in conscious rat 
Saline 
pH 
Pco2, mmHg 
Po2,mmHg 
Lactic acid, mmol/l 
TRH, 2 mg/kg 
pH 
Pco2, mmHg 
Po2, mmHg 
Lactic acid, mmol/1 
n 
5 
7 
CG3703, 0.5 mg/kg 5 
c 
7.47±0.01 
30±1 
92±3 
1.3±0.2 
1.44±0.01 
32±1 
93±3 
1.4±0.1 
EOB 
7.48±0.03 
18±1 
125±1 
7.2±1.0 
7.47±0.02 
21±1 
129±4 
6.8±0.4 
30 
7.45±0.03 
24±1 
126±3 
4.9±0.3 
7.45±0.01 
26±2 
112±4* 
4.9±0.6 
Minutes After EOB 
60 
7.46±0.03 
26±2 
125±3 
4.1±0.7 
7.44±0.01 
27±1 
113±4 
3.6±0.5 
90 
7.46±0.03 
27±2 
123±2 
3.1±0.6 
7.43±0.01 
29±1 
108±2t 
2.8±0.4 
120 
7.44±0.02 
28±2 
123±3 
2.8±0.6 
7.44±0.01 
30±1 
102±3t 
2.4±0.2 
pH 7.45±0.01 7.43±0.03 7.44±0.01 7.46±0.03 7.47±0.02 7.48±0.03 
Pco2, mmHg 32±1 21±2 23±1 22±2 24±2 23±3 
Po2, mmHg 86±2 118±5 110±2t 117±5 108±1t 108±3t 
Lactic acid, mmol/l 1.3±0.3 7.5±1.3 5.9±0.8 5.2±0.8 4.5±0.8 3.7±0.6 
Values are means ± SEM. TRH, thyrotropin releasing hormone; CG3703, analogue of TRH; EOB, end of ble~ng; C, control period before 
hemorrhage. TRH, CG3703 or salinewas injected into the arterialline 2-3 min after bleeding 8.5 ml·300 g-1·5 mm-1. • P < 0.05; t P < 0.01 
vs. saline-treated group (Student-Newman-Keuls test). 
TABLE 2. Elfect of TRH and CG3703 on survival 
in conscious rats exposed to hemorrhage 
45% Hemorrhage, 27% Hemorrhage, 
Treatment h After EOB h After EOB 
2 24 2 24 
Saline 17/0 14/3 13/4 7/0 7/0 6/0 
TRH, 8/3* 7/4 7/4 NT NT NT 
2 mg/kg ia 
CG3703, 17/3 13/7 7/13t 7/1 6/2 5/3 
0.5 mg/kg ia 
Values are survival ratios (alive/dead). TRH, thyrotropin releasing 
hormone; EOB, end of bleeding; NT, not tested. Drugs were injected 
into the arterial line 2-3 min after EOB. • P = 0.05; t P = 0.01 vs. 
saline-treated group (Fisher's exact probability test). 
and reduced perfusion in renal ( and to a lesser degree in 
mesenteric) vascular beds witb opposite cbanges in vas-
cular resistance after intracerebroventricular (0.8-80 
nmol/kg) or intravenous (2 mg/kg) injections of TRH 
(23). Thus tbese differential effects of TRH on local 
blood flow and vascular resistance in intact versus hem-
orrhaged animals may, at least in part, explain the dis-
crepancy in its hemodynamic effects in. normovole~ic 
versus hypovolemic state. In hypovolem1c bypotens10n 
TRH further increased tbe bleeding-induced impairment 
of local blood flow to essential organs and increased 
vascular resistance. Tbe general vascular constriction led 
to the elevation of total peripberal resistance and mean 
arterial pressure. 
Hemorrhage (45%) induced complex derangements of 
blood chemistry; blood Iactate Ievels increased, and blood 
Pco2 decreased, wbile there was no significant change in 
blood pH. Tbis might be due to tbe opposing effects of 
lactic acidosis and respiratory alkalosis caused by hyper-
ventilation. Furtbermore, due to tbe byperventilation, 
the blood Po2 significantly increased after tbe bleeding. 
The hyperoxemia in the saline-treated animals was seen 
throughout the experimental period of 2 h, whereas, in 
the TRH- or CG3703-treated rats, the Po2 Ievels de-
creased rapidly after the hemorrhage, reaching almost 
the prehemorrhage Ievel within 2 h after the end of the 
bleeding. This might further contribute to the detrimen-
tal effect of TRH and its analogue in hemorrhage. Fur-
tbermore, tbe TRH analogue, CG3703, had a moderate 
cardiodepressant effect in conscious rats exposed to 
bleeding. The reduction in cardiac output could cause 
impairment of ventilation-to-perfusion ratio, tbereby di-
minishing the amount of 02 supplied to tissues. The 
decrease in tissue 0 2 supply might then, together with 
tbe impairment of regional blood flow in vital organs, 
explain the increased mortality in the 45% hemorrhage 
both after native TRH or CG3703. 
Tbough tbe beneficial effect of TRH on blood pressure 
in various experimental shock models is weil known (for 
review see Ref. 3), very few studies are available that 
report the effect of TRH on survival rate in tbese shock 
models. Holaday et al. (15) reported increased short-term 
survival (2 h after the shock) by TRH in endotoxic shock 
in tbe rat but bad no data about tbe survival rates in 
hemorrhagic shock (13). Some preliminary sturlies on 
primates (11, 21), on the otber band, suggest a beneficial 
effect of TRH on survival in bemorrbagic, but not in 
endotoxic, shock. Recently, a drastic increase in survival 
by centrally injected TRH was reported in anaphylactic 
sbock in mice (1). Our present results clearly show that 
the TRH analogue, CG3703, significantly decreased sur-
vival rate in bypovolemic bypotension 24 h after the 
bleeding, wbile tbe short-acting natural TRH caused a 
decline in survival only 1 h after the bleeding. These 
findings may suggest that the beneficial effect of TRH 
is dependent on tbe sbock model as well as on tbe species 
studied. Thus TRH and stable analogues may prove to 
be beneficial in anaphylactic shock, whereas in bypovo-
lemia TRH reverses the bypotension mainly by increas-
ing vascular resistance which Ieads to a sustained reduc-
tion in blood flow to vital organs thereby exacerbating 
the sbock and promoting deatb. 
The authors thank Ferne Robinson and Heidi Hatton for their help 
in preparing this manuscript. . . . . 
This work was supported in part by Umformed Serv1ces Umvers1ty 
of Health Seiences Protocol R09211. 
TRH IN HYPOVOLEMIC HYPOTENSION HllOl 
The opinions or assertions contained herein are the private ones of 
the authors and are not to be construed as official or reflecting the 
view of the Department of Defense or the Uniformed Services Univer-
sity of the Health Sciences. The experiments reported herein were 
conducted according to the principles set forth in the "Guide for the 
Care and Use of Laborstory Animals," Institute of Laborstory Anima) 
Resources, National Research Council (DHEW Publiestion no. NIH 
78-23, 1978). 
Received 17 June 1985; accepted in final form 21 January 1986. 
REFERENCES 
1. AMIR, S., M. HAREL, AND A. SCHACHAR. Thyrotropin-re)easing 
hormone (TRH) improves survival in anaphylactic shock: a central 
effect mediated by the sympatho-adrenomedullary ß-adrenoceptive 
system. Brain Res. 298: 219-224, 1984. 
2. BEALE, J. S., R. P. WHITE, AND S.-P. HUANG. EEG and blood 
pressure effects the TRH in rabbits. Neuropharmacology 16: 499-
506, 1977. 
3. BERNTON, E. W., J. B. LONG, AND J. W. HOLADAY. Opiods and 
neuropeptides: mechanism in circulatory shock. Federation Proc. 
44: 290-299, 1985. 
4. BROWN, M. R. Thyrotropin releasing factor: a putative CNS reg-
ulator of the autonomic nervous system. Life Sei. 28: 1789-1795, 
1981. 
5. Drz, I. D., AND K. M. JACOBOWITZ. Cardiovascular effects produced 
by injections of thyrotropin-releasing hormone in specific preoptic 
and hypothalamic nuclei in the rat. Peptides 5: 801-808, 1984. 
6. FADEN, A. I. Neuropeptides in shock and CNS injury: potential 
clinical applications. In: The Pharmacologic Approach to the Criti-
cally JU Patient. Baltimore, MD: Williams & Wilkins, 1983, p. 636-
649. 
7. FEUERSTEIN, G., W. E. LUX, JR., D. EZRA, E. C. HAYES, F. 
SNYDER, AND A. I. FADEN. Thyrotropin releasing hormone blocks 
the hypotensive effects of platelet activating factor in the unanes-
thetized guinea pig. J. Cardiovasc. Pluzrmacol. 7: 335-340, 1985. 
8. FEUERSTEIN, G., A. H. HASSEN, AND A. I. FADEN. TRH: cardio-
vascular and sympathetic modulation in brain nuclei of the rat. 
Peptides 4: 617-620, 1983. 
9. FEUERSTEIN, C., Z. ZUKOWSKA·GROJEC, M. BAYORH, I. J. KOPIN, 
AND A. I. FADEN. Leukotriene n.-induced hypotension is reversed 
by thyrotropin releasing hormone. Prostaglandins 26: 711....:724, 
1983. 
10. FRIDERICHS, E., E. SCHWERTNER, S. HERRLING, W.-A. G'ONZLER, 
F. ÜTTING, AND L. FLOHt. Activity of thyroliberin analogs with a 
modified pyroglutamyl residue on the central nervous system. In: 
Structure and Activity of Natural Peptides. Berlin: Gruyter, 1981, 
p. 461-481. 
11. GURLL, N. J., D. G. REYNOLDS, J. HOLADAY, AND E. GANES. 
lmproved cardiovascular function and survival using thyrotropin 
releasing hormone (TRH) in primate hemorrhagic shock (Ab-
stract). Physiologist 25: 342, 1982. 
12. HAYWOOD, J. R., R. A. SHAFFER, C. FASTENOW, G. D. FINK, AND 
M. J. BRODY. Regional blood flow measurement with pulsed Dop-
pler flowmeter in conscious rat. Am. J Physiol. 241 (Heart Circ. 
Physiol. 10): H273-H278, 1981. 
13. HOLADAY, J. W., R. J. D'AMATO, AND A. I. FADEN. Thyrotropin-
releasing hormone improves cardiovascular function in experimen • 
tal endotoxic and hemorrhagic shock. Science Wash. DC 213: 216-
218, 1981. 
14. HOLADAY, J. W., AND A.l. FADEN. Thyrotropin releasing hormone: 
autonomic effects upon cardiorespiratory function in endotoxic 
shock. Reg. Peptides 7: 111-125, 1983. 
15. HOLADAY, J. W., B. A. RUVIO, AND A. I. FADEN. Thyrotropin-
releasing hormone improves blood pressure and survival in endo-
toxic shock. Eur. J. Pharmacol. 74: 101-105, 1981. 
16. KOIVUSALO, F., I. PAAKKARI, J. LEPPÄLUOTO, AND H. KARPPA· 
NEN. The effect of centrally administered TRH on blood pressure, 
heart rate and ventilation in rat. Acta Physiol. Scand. 106: 83-86, 
1979. 
17. Lux, W. E., JR, G. FEUERSTEIN, AND A. I. FADEN. Alteration of 
leukotriene D2 hypotension by thyrotropin releasing hormone. 
Nature Lond. 302: 822-824, 1983. 
18. LUX, W. E., JR., G. FEUERSTEIN, AND A. I. FADEN. Thyrotropin 
releasing hormone reverses experimental anaphylactic shock 
through non endorphin related mechanism. Eur. J. Pharmacol. 90: 
301-302, 1983. 
19. METCALF, G. Regulatory peptides as a source of new drugs-the 
clinical prospects for analogues of TRH which are resistant to 
metabolic degradation. Brain Res. Reu. 4: 389-408, 1982. 
20. PRASAD, C. Thyrotropin·releasing hormone. In: Handbook of Neu-
rochemistry. New York: Plenum, 1985, p. 175-200. 
21. REYNOLDS, 0. G., N. J. GURLL, J. HOLADAY, AND E. GANES. 
Thyrotropin releasing hormone (TRH) in primate endotoxic shock 
(Abstract). Physiologist 25: 309, 1982. 
22. SALGADO, M. C. 0., AND E. M. KRIEGER. Cardiac output in 
unrestrained conscious rats. Clin. & Exp. Pharmacol. Physiol., 
SuppL 3: 165-167, 1976. 
23. SIREN, A.-L., AND G. FEUERSTEIN. Effect of thyrotropin releasing 
hormone on blood pressure and peripheral blood flow in conscious 
rats (Abstract). Federation Proc. 44: 721, 1985. 
24. WATANABE, K., K. T. NISHIO, C. MORI, M. KIHARA, AND Y. 
Y AMORI. Measurement of cardiac output by the thermodilution 
method in conscious spontaneously hypertensive rats. Jpn. Heart 
J. 25: 1051-1058, 1984. 
